Custom crystal tombstone marking a private placement by Rezolute, a California-based clinical stage biopharmaceutical firm.
(9ALJ067)
Whether you’re celebrating a funding round, research collaboration, FDA-approval, or commemorating a deal in the biotech space, you’ll find inspiration in the custom designs below.
Custom crystal tombstone marking a private placement by Rezolute, a California-based clinical stage biopharmaceutical firm.
(9ALJ067)Logo-themed crystal tombstone commemorating a private placement by NovaBay Pharmaceuticals. The biopharmaceutical company is based Emeryville, California.
(9AMF250)Custom Lucite deal toy commemorating Series B funding for Pharmatech, the developer of a drug therapy for dementia.
(9AJH103)Crystal deal toy commemorating a follow-on offering by Gritstone Oncology, a clinical-stage biotechnology firm focused on cancer immunotherapies. Goldman Sachs and Cowen and Company acted as joint book-running managers for the offering.
(9ALJ202)Custom crystal tombstone commemorating clinical trial financing provided for biopharmaceutical company, Clovis Oncology. The clinical trial sponsored by Clovis involves an ovarian cancer study.
(9ALJ233)Custom Lucite, with an embedded champagne cork, celebrating the approval by the Food and Drug Administration (FDA) of the obesity treatment Plenity. Plenity was developed by Boston-based biotech firm Gelesis.
(9AMF149)Custom Lucite deal toy commemorating the acquisition of San Diego-based Ultimate Labs, a testing laboratory for the pharmaceutical, biotechnology, medical device, and food industries.
(9ALJ145)Custom crystal award featuring a 3-D etch of a DNA strand.
(9ACJ007)Custom Lucite tombstone commemorating equity financing for Georgetown, Texas-based biotech firm DisperSol Technologies.
(9ACJ018)Beginning on this page, you’ll find galleries with over 90 images of financial tombstones and deal toys from the biotech and life sciences space. You’ll find a number of custom designs playing off visual elements commonly associated with this space, including DNA strands, pills, lab beakers, periodic tables, as well as ones incorporating actual drug vials.
As you might also expect, you’ll see a number of deal toys involving internationally recognized firms and players. These include Takeda Pharmaceutical, Horizon Therapeutics, Gilead Sciences, Roche, Neurocrine, and Bayer. You’ll see as well tombstones commemorating transactions common to this sector involving these and other firms: joint ventures, licensing deals, and development and commercialization agreements.
But you’ll also notice a number of deals commemorated here that may involve far less familiar firms. These include the acquisition of a Dutch company focused on live-cell imaging analytics, and one of an Illinois-based gene therapy firm devoted to the treatment of a rare genetic disorder; the initial public offering of an Australian developer of radiopharmaceutical cancer therapies, and the IPO of a Norwegian biotech making use of marine compounds such as herring roe extract; early-stage funding for a Philadelphia gene engineering startup, and the IPO of an Israeli firm focused on medical applications for lipid-based compounds.
You’ll also notice in these galleries designs not related to any financial transaction. These celebrate a range of awards and employee recognition pieces honoring successful clinical trials, Food and Drug Administration (FDA) and New Drug Application (NDA) submissions, research collaborations and partnerships, and product development milestones.
"*" indicates required fields
